Back to results
TerminatedPhase 2

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

NCT00517361

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

University of Chicago

Chicago, Illinois, United States

+1 additional location

View on ClinicalTrials.gov
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer — TrialFind